---
title: Improve cough strength using SpiroGym
nct_id: NCT06481540
phase: NA
status: RECRUITING
sponsor: General University Hospital, Prague
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06481540"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06481540"
last_fetched: "2026-05-10T14:04:36.816Z"
source: "Parkinson's Pathways (curated)"
---
# Improve cough strength using SpiroGym

**Goal (in five words):** Improve cough strength using SpiroGym

**Official Title:** Effect of the SpiroGym App on Voluntary Cough Strength in Parkinson's Disease

**Trial ID:** [NCT06481540](https://clinicaltrials.gov/study/NCT06481540)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** General University Hospital, Prague
- **Target Enrollment:** 60 participants
- **Start Date:** 2024-01-01
- **Completion Date:** 2025-05
- **Conditions:** Parkinson Disease, Voluntary Peak Cough Strength, mHealth
- **Interventions:** Expiratory muscle strength training + SpiroGym application, Expiratory muscle strength training
- **Intervention Types:** DEVICE

## Summary For Families

Aiming to boost voluntary cough strength so people with Parkinson's can clear their airways better and lower the risk of choking or chest infections. The program uses expiratory muscle strength training, which exercises the muscles that drive a strong cough by breathing out against resistance, and the SpiroGym app guides, times, and tracks those training sessions to keep practice consistent. It is a non‑drug, at-home approach that is intended to be used alongside your usual Parkinson's medications, which should be on a stable dose. Looking for adults 40 to 80 years old with Parkinson's on stable dopaminergic therapy; people with other neurological diseases, significant cognitive impairment (MoCA <19), breathing disorders, recent smoking, or uncontrolled high blood pressure are excluded.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of Parkinsons disease
* Stable dopaminergic medication (stable dose for at least 1 month)

Exclusion Criteria:

* Other neurological disorders
* Difficulty complying due to neuropsychological dysfunction (dementia with a score of less - - than 19 on the Montreal Cognitive Assessment)
* Breathing disorders or diseases
* Smoking in the past 5 years
* Uncontrolled hypertension
```

## Locations (1)

- General University Hospital, Prague, Czechia _(50.0880, 14.4208)_
  - Martin Srp, PhD — (CONTACT) — +420224965513 — martin.srp@vfn.cz
  - Martin Srp, PhD — (CONTACT) — 224965513 — martin.srp@vfn.cz

## Central Contacts

- Martin Srp, PhD — (CONTACT) — +420224965513 — martin.srp@vfn.cz

---

*Canonical: https://parkinsonspathways.com/trial/NCT06481540*  
*HTML version: https://parkinsonspathways.com/trial/NCT06481540*  
*Source data: https://clinicaltrials.gov/study/NCT06481540*